| Dr Mal Rolland Homan, MD | |
|
1243 S Cedar Crest Blvd, Suite 2800, Allentown, PA 18103-6268 | |
| (610) 402-6790 | |
| Not Available |
| Full Name | Dr Mal Rolland Homan |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 39 Years |
| Location | 1243 S Cedar Crest Blvd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215905898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD036464E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Lehigh Valley Hospital - Pocono | East stroudsburg, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
| Entity Name | Guthrie Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962451153 PECOS PAC ID: 6002728656 Enrollment ID: O20040301000571 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
| Entity Name | Schuylkill Health System Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588603567 PECOS PAC ID: 0840285532 Enrollment ID: O20040420001197 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
| Entity Name | Hazleton Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952464638 PECOS PAC ID: 8022110402 Enrollment ID: O20070305000195 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mal Rolland Homan, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: () - | Dr Mal Rolland Homan, MD 1243 S Cedar Crest Blvd, Suite 2800, Allentown, PA 18103-6268 Ph: (610) 402-6790 |
News Archive
Tenet Healthcare Corporation announced that it has entered into an agreement as part of an industry-wide settlement with the United States Department of Health and Human Services, the Secretary of HHS, and the Centers for Medicare & Medicaid Services that is expected to result in approximate net cash proceeds to Tenet of $84 million, of which $77 million is expected to relate to continuing operations.
Researchers at RCSI, Stanford University and Oregon Health Sciences University have discovered a marker which can help determine which asthma patients are likely to benefit from a new treatment which targets inflammatory cells called Eosinophils.
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular defects associated with Smith-Lemli-Opitz syndrome (SLOS) by modeling this disease using induced pluripotent stem cells.
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.
› Verified 2 days ago
Jessica Mary Boehmler, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 205, Allentown, PA 18103 Phone: 610-439-8856 Fax: 610-439-8856 | |
Allison Jane Baragona, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1501 N Cedar Crest Blvd Ste 110, Allentown, PA 18104 Phone: 610-821-2828 Fax: 610-821-7915 | |
James A Burke, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 300, Allentown, PA 18103 Phone: 610-402-3110 Fax: 610-402-3112 | |
Stephen R Shore, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1901 Hamilton St Ste 300, Allentown, PA 18104 Phone: 610-628-7900 Fax: 833-816-7513 | |
Tarika Sejal Chowdhary, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 17th & Chew, Suite 101, Allentown, PA 18105 Phone: 610-969-4370 | |
Ashley Vojtek, DO Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 484-862-3200 | |
Dr. Ian William Klansek, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2490 Schoenersville Rd, Allentown, PA 18109 Phone: 484-526-7262 |